Literature DB >> 28501510

Surface engineering for lymphocyte programming.

Elana Ben-Akiva1, Randall A Meyer2, David R Wilson2, Jordan J Green3.   

Abstract

The once nascent field of immunoengineering has recently blossomed to include approaches to deliver and present biomolecules to program diverse populations of lymphocytes to fight disease. Building upon improved understanding of the molecular and physical mechanics of lymphocyte activation, varied strategies for engineering surfaces to activate and deactivate T-Cells, B-Cells and natural killer cells are in preclinical and clinical development. Surfaces have been engineered at the molecular level in terms of the presence of specific biological factors, their arrangement on a surface, and their diffusivity to elicit specific lymphocyte fates. In addition, the physical and mechanical characteristics of the surface including shape, anisotropy, and rigidity of particles for lymphocyte activation have been fine-tuned. Utilizing these strategies, acellular systems have been engineered for the expansion of T-Cells and natural killer cells to clinically relevant levels for cancer therapies as well as engineered to program B-Cells to better combat infectious diseases.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Artificial antigen presenting cell; Lymphocyte engineering; Microparticle; Nanoparticle

Mesh:

Substances:

Year:  2017        PMID: 28501510      PMCID: PMC5688954          DOI: 10.1016/j.addr.2017.05.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  136 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

3.  The growth of B cell receptor microcluster is a universal response of B cells encountering antigens with different motion features.

Authors:  Zhengpeng Wan; Wanli Liu
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

Review 4.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

5.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

6.  Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.

Authors:  Enock Anassi; Uche Anadu Ndefo
Journal:  P T       Date:  2011-04

Review 7.  B cells responses and cytokine production are regulated by their immune microenvironment.

Authors:  Monica I Vazquez; Jovani Catalan-Dibene; Albert Zlotnik
Journal:  Cytokine       Date:  2015-03-02       Impact factor: 3.861

Review 8.  Antigen-presenting cell types.

Authors:  S C Knight; A J Stagg
Journal:  Curr Opin Immunol       Date:  1993-06       Impact factor: 7.486

9.  Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells.

Authors:  Despina Rudolf; Tobias Silberzahn; Steffen Walter; Dominik Maurer; Johanna Engelhard; Dorothee Wernet; Hans-Jörg Bühring; Gundram Jung; Byoung S Kwon; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Cancer Immunol Immunother       Date:  2007-07-27       Impact factor: 6.968

10.  Cytoskeletal forces during signaling activation in Jurkat T-cells.

Authors:  King Lam Hui; Lakshmi Balagopalan; Lawrence E Samelson; Arpita Upadhyaya
Journal:  Mol Biol Cell       Date:  2014-12-17       Impact factor: 4.138

View more
  8 in total

1.  Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.

Authors:  Muhammad Raisul Abedin; Kaitlyne Powers; Rachel Aiardo; Dibbya Barua; Sutapa Barua
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

Review 2.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

Review 3.  Polymeric micro- and nanoparticles for immune modulation.

Authors:  Elana Ben-Akiva; Savannah Est Witte; Randall A Meyer; Kelly R Rhodes; Jordan J Green
Journal:  Biomater Sci       Date:  2018-12-18       Impact factor: 6.843

4.  Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.

Authors:  Kelly R Rhodes; Ariel Isser; John W Hickey; Elana Ben-Akiva; Randall A Meyer; Alyssa K Kosmides; Natalie K Livingston; Stephany Y Tzeng; Jonathan P Schneck; Jordan J Green
Journal:  ACS Appl Mater Interfaces       Date:  2021-02-12       Impact factor: 10.383

5.  Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils the Characteristics of the Immune Microenvironment and Prognosis Signature in Prostate Cancer.

Authors:  Ruisong Wang; Yaqian Xiao; Meisen Pan; Zhongyuan Chen; Pinhong Yang
Journal:  J Oncol       Date:  2022-07-19       Impact factor: 4.501

Review 6.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

Review 7.  Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.

Authors:  Chaopin Yang; Yue Li; Yaozhang Yang; Zhiyi Chen
Journal:  J Immunol Res       Date:  2020-01-21       Impact factor: 4.818

8.  In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.

Authors:  Stephany Y Tzeng; Kisha K Patel; David R Wilson; Randall A Meyer; Kelly R Rhodes; Jordan J Green
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-07       Impact factor: 12.779

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.